Impact of Bupivacaine on malignant proliferation, apoptosis and autophagy of human colorectal cancer SW480 cells through regulating NF-κB signaling path

Bingwu Liu\textsuperscript{a}, Xinfei Yan\textsuperscript{a}, Zuojia Hou\textsuperscript{b}, Lei Zhang\textsuperscript{c}, and Duwen Zhang\textsuperscript{d}

\textsuperscript{a}Department of Anesthesiology, The Second Children and Women’s Healthcare of Jinan City, Jinan City, Shandong Province, China; \textsuperscript{b}Department of Anesthesiology, Laiwu People’s Hospital of Jinan City, Jinan City, Shandong Province, China; \textsuperscript{c}Department of Anesthesiology, Laiwu Iron and Steel Group Laiwu Mining Co., Ltd. Staff Hospital, Jinan City, Shandong Province, China; \textsuperscript{d}Department of Anesthesiology, Guizhou Provincial People’s Hospital, Guiyang City, Guizhou Province, China

ABSTRACT

To probe into the impact of Bupivacaine on colorectal cancer (CRC) proliferation, apoptosis, and autophagy through regulating the NF-κB signaling pathway. Our work treated CRC cells with Bupivacaine, detected cell vitality through MTT assay, apoptosis through flow cytometry, cell migration through wound healing assay, NF-κB activity through immunofluorescence, inflammatory factor level, including TNF-α, IL-1β as well as IL-6 through ESLIA, apoptosis factor mRNA expression, including Bcl-2, Bax and caspase-3q through qRT-PCR, and protein expression linking with NF-κB signaling pathway as well as autophagy-related proteins via western blot. In in vivo experiments, we explored the impact of Bupivacaine on tumor volume, tumor and NF-κB expression. The results showed that 1 mM Bupivacaine was available to signalingly inhibit CRC cell vitality, promoted apoptosis rate and apoptosis gene expression, as well as IL-6 expression. In short, bupivacaine is available to inhibit CRC proliferation through regulating NF-κB signaling pathway, promote apoptosis and autophagy, and can be used as a potential drug to treat CRC in the future.

CONTACT Duwen Zhang \textsuperscript{h} zhangdw_3@hotmail.com \textsuperscript{h} Department of Anesthesiology, Guizhou Provincial People’s Hospital, 83 East Zhongshan Road, Guiyang City, Guizhou Province, 550002, China

\textsuperscript{h} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1 Introduction

Colorectal cancer (CRC), a universal gastrointestinal tumor, has become the fourth most universal reason for cancer death worldwide [1]. At present, the treatment mainly depends on surgical excision combined with chemotherapy and radiotherapy, but for patients with advanced CRC, survival rate is difficult to improve [2,3]. The surgical efficacy is usually reduced by cancer at high risks of recurrence [4]. The previous studies have reported that the type of anesthetics applied during surgical excision links with a long-term prognosis of cancer [5,6]. Additionally, researchers recently have revealed that an inhaled anesthetic called sevoflurane inhibits CRC migration as well as invasion through regulating miR-203/Extracellular regulatory protein kinase/human matrix metalloproteinase 9 pathway. Based on retrospective research, local anesthesia is available to reduce cancer cell metastasis along with recurrence in patients undergoing surgery [7,8], indicating that anesthetics may act pivoting in cancer development and poor prognosis.

Bupivacaine is a local anesthetic connected to acrylamide, commonly applied in surgically removing tumors [9]. Previous studies have revealed that Bupivacaine is available to regulate ras homologous family member A/Rho-related kinase/myosin light chain pathway to inhibit gastric cancer migration [10]. Additionally, studies have reported that Bupivacaine has shown direct anti-cancer impact through activating phosphorylation of Glycogen synthase kinase-3 beta pathway. Recently, researchers found that Bupivacaine inhibited CRC proliferation and migration, but without adverse effects on patients undergoing CRC surgery [11,12].

However, although some progress has been made in the research of Bupivacaine inhibiting cancer, its potential molecular mechanism as a local anesthetic affecting cancer cell biology have not yet been fully identified. This research was to probe into the impact of Bupivacaine on human CRC cell proliferation, apoptosis as well as autophagy, and highlighting its impact on nuclear factor kappa B (NF-kB) signaling pathway in CRC cell.

2 Methods

2.1 Cell culture

Our team purchased human CRC cells (SW480 & SW620) and human normal colorectal epithelial cell line (FHC) from CAS (China) cell bank, cultured cells in RPMI-1640 mediums (Sigma Aldrich, USA), added 10% newborn calf serum to the medium (HyClone, New Zealand), 1% L-glutamine as well as 1% penicillin-streptomycin (Sigma Aldrich), kept cells in air jacket incubator (Triple Red, UK) with 5% CO₂, at 37°C, cultured all cells in 24-well plates, applied in experiments when cell fusion reached 70–80%, treated the cells with 1 μM-1 mM Bupivacaine for further experiments after 24 or 48 hours.

2.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide (MTT) assay for detecting cell viability

In accordance with the instructions from manufacturer, we applied MTT assay kit (Sangon Biotech, China) to detect cell proliferation, seeded the cells into 96-well plate, cultured them with 1 μM-1 mM Bupivacaine in 24 or 48 h, added 0.5 mg/mL MTT, incubated them for 4 h, removed the supernate, added DMSO, and measured the absorbance at 570 nm through enzyme-labeled instrument.

2.3 Flow cytometry for detecting cell apoptosis

The cell apoptosis was detected as described previously [13]. In accordance with the instructions from manufacturer, we collected cells and dyed them with fluorescein isothiocyanate-annexin V and propylene iodide through AV-FITC/PI apoptosis detection kit (Keygen, China). Our team measured AV/PI-positive cells via flow cytometry.

2.4 Cell scratch assay

Cultured the cells in a 60 mm culture plate to form a single layer of convergence, later scratched the single layer with a 1 mL of pipettes tip and washed twice with medium. Before taking each image, we made a mark at the bottom of the plate to be sure that all images were taken in the same location, where
our team taken a second image 24 h after another occurrence with or without Bupivacaine at different concentrations. Based on these images, we compared the wound healing through Image-Pro Plus software (Media Cyber nets in the United States).

### 2.5 Immunofluorescence

Fixed SW480 and SW620 cells in 4% polyformaldehyde, then sealed them in PBST (Sigma Aldrich) with donkey serum for 1 h before inoculation with the primary antibody: NF-κB (3039, 1:1000, Cell Signaling Technology) overnight in PBST at 4°C, adding FITC or rhodamine-coupled secondary resistance (1:400, Millipore, UK). Later our group re-dyed the slides with 4', 6-diamidino-2-phenylindole (DAPI Dye) as well as examined them through Olympus BX4 microscope (Watford, UK). At last, we quantified immunofluorescence using ImageJ (National Institutes of Health, Maryland).

### 2.6 Enzyme-linked immunosorbent assay (ELISA)

In accordance with the instructions from manufacturer, our team measured interleukin 1β (IL-1β), Tumor Necrosis Factor α (TNF-α) and Interleukin 6 (IL-6) levels through ELISA kits (BD Biosciences, USA) in market.

### 2.7 Real-time fluorescent quantitative PCR (qRT-PCR)

In accordance with the instructions from manufacturer, our team extracted the total RNA from the cell using TRizol reagent (Invitrogen), the RNA samples were processed with DNase, and the purity and concentration of total RNA were determined using an ultraviolet spectrophotometer (Eppendorf, Hamburg, Germany). transferred RNA as complementary DNA (cDNA) through PrimeScript reverse transcriptase kits (Takala City, Liaoning Province, China), performed qRT-PCR on the ABI StepOnePlus™ Real-Time PCR System (American Apple Biosystems) through SYBR Green Mix, applied glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal references, and represented quantitative values through 2-ΔΔCt. The primer sequences are listed in Table 1.

### 2.8 Western blot

Western blot was performed as previously described [14]. Extracted the total protein from cells via RIPA lysis buffer (Beyotime, China) and measured protein concentration via BCA protein assay kit (Thermo Fisher, USA), separated the protein samples on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as well as transferred them to polyvinylidene difluoride (PVDF; EMD, Millipore) containing 5% skimmed milk. Later incubated PVDF at 4°C with primary antibody NF-κB (8248, 1:1000) inhibitor of NF-xB (IkB, 9242, 1:1000), phosphorylated IkB (p-IkB, 2859, 1:1000), IkB kinase (IKK, 2682, 1: 1000), phosphorylated IKK (p-IKK, 2697, 1:1000), microtubule-associated protein light chain 3B (LC3B, 2775, 1:1000), Beclin-1 (3495, 1:1000), p62 (5114, 1:1000) from Cell Signalling Technology as well as anti-GAPDH (ab8245, 1:1000) from Abcam. Later, we put them and horseradish peroxidase-coupled-secondary antibody LgG H&L (HRP, 1:2000, ab6721, Abcam) altogether, applied Western Lightning Plus-ECL to visualize protein band and LAS-3000 Luminescent Image Analyzer (Fujifilm) for band analysis.

### 2.9 Tumor xenograft

The xenotransplantation experiment was performed as described previously [15]. For animal research, our team obtained 24 male Specific Pathogen Free-grade BALB/c nude mice from the The Second Children and Women’s Healthcare of Jinan City Animal Center and put them in conventional facilities, carried out all animal research

| Table 1. qRT-PCR primer sequence. |
|-----------------------------------|
| GAPDH | Forward: 5'-CCTCGTCTCATAGCAAGATGCT-3' |
|       | Reverse: 5'-GGGTAGTGACTTCTGGAGAT-3' |
| Bcl-2  | Forward: 5'- GTGGTTGGACAACTCGCTCTG-3' |
|        | Reverse: 5'-GGTCTGCTGACCTCCTTGTG-3' |
| Bax    | Forward: 5'- GGATCGAGCAGAGAGATGGA3' |
|        | Reverse: 5'- GGATCGAGCAGAGAGATGGA3' |
| Caspase-3 | Forward: 5'- TGTTGAGTGACGAGTGGGGA3' |
|        | Reverse: 5'- TGTTGAGTGACGAGTGGGGA3' |
in accordance with the guidelines of the Animal Care and Use Committee of the Second Children and Women’s Healthcare of Jinan City Hospital and has been approved by the Animal Care and Use Committee, as well as allocated the animals into 4 groups: Control I Group, Model I Group, Control II Group, and Model II Group. We injected SW480 cells (1.5 × 10⁶) into Control I and model I groups through subcutaneous injection, and SW620 cells (1.5 × 10⁶) into Control II and Model II groups through subcutaneous injection. Subsequently, our team injected 0.1 mL of physiological saline into Control I and Control II groups, and injected the same volume of 4.3 mM and 8.6 mM Bupivacaine into Model I and Model II groups, respectively, once a day for 5 times. We weekly recorded the radius (a) and diameter (b) of tumor with vernier caliper, as well as calculated its volume. The calculation of tumor volume: \[ V = \frac{\text{long diameter} \times \text{wide diameter}}{2} \].

2.10 Data analysis

Our work expressed the experimental results as mean ± standard deviation, applied SPSS 22 software for data analysis, combined with Student’s T test detection and one-way analysis of variance (ANOVA), applied Tukey’s test to make multiple variance corrections to the sample, and significant differences existed in experimental groups when \( P < 0.05 \).

3 Results

3.1 Bupivacaine inhibited CRC cell proliferation

To probe into the impact of Bupivacaine on CRC cell vitality, our team treated CRC cells for 24 or 48 hours with 1 μMm-1 mM Bupivacaine. As

Figure 1. Bupivacaine Inhibited CRC Cell Proliferation.

Note: A & B: MTT Assay For Checking SW480 Cell Activity After Receiving 1 μm-1 mm Bupivacaine In 24 And 48 h; C & D: MTT Assay For Checking SW620 Cell Activity After Receiving 1 μm-1 mm Bupivacaine In 24 And 48 h; E & F: MTT Assay For Checking FHC Cell Activity After Receiving 1 μm-1 mm Bupivacaine In 24 And 48 h; Data Shown In Mean ± SD (N = 3); One-Way ANOVA For Calculating The Significance Of Each Group; Applying The Tukey Test For Correcting The Variance. *P < 0.05.
shown in Figure 1a-1d, 1 mM Bupivacaine visually inhibited SW480 and SW620 cell vitality. Cell vitality after receiving Bupivacaine in 48 h was lower than that after receiving Bupivacaine in 24 h. However, 1 mM Bupivacaine had no significant impact on FHC cell vitality in normal CRC cell line (Figure 1e-f). This suggests that Bupivacaine is available to inhibit CRC proliferation.

3.2 Bupivacaine inhibited CRC cell migration

Examined the influence of 1 mM Bupivacaine on CRC cells migration through scratch assay. As

![Figure 2. Bupivacaine Inhibited CRC Cell Migration. Note: A & B: Cell Scratch Test For Checking The Cell Migration Capacity In SW480 And SW620 Cells After Receiving 1 mm Bupivacaine In 24 And 48 h; Data Shown In Mean ± SD (N = 3); One-Way ANOVA For Calculating The Significance Of Each Group; Applying The Tukey Test For Correcting The Variance. *P< 0.05.](image)

![Figure 3. Bupivacaine Promoted CRC Cell Apoptosis. Note: A & B: Flow Cytometry For Checking The Cell Apoptosis Rete In SW480 And SW620 Cells After Receiving 1 mm Bupivacaine In 24 And 48 h; C & D: Qrt-PCR For Checking Bcl-2, Bax And Caspase-3 Mrna Expression Levels In SW480 And SW620 Cells After Receiving 1 mm Bupivacaine In 24 h And 48 h; Data Shown In Mean ± SD (N = 3); One-Way ANOVA For Calculating The Significance Of Each Group; Applying The Tukey Test For Correcting The Variance. *P< 0.05.](image)
shown in Figure 2a-2d, SW480 and SW620 cell migration were signally reduced after after receiving 1 mM Bupivacaine in 24 or 48 h in comparison with those in control group. This implies that Bupivacaine is available to inhibit CRC migration.

3.3 Bupivacaine promoted CRC cell apoptosis

Examined the influence of 1 mM Bupivacaine on CRC cells apoptosis through flow cytometry. As shown in Figure 3a-3b, a significant increase in apoptosis rate of SW480 and SW620 cells after receiving Bupivacaine in 24 or 48 h, featuring time dependency. Additionally, Bupivacaine inhibited Bcl-2 expression in SW480 and SW620 cells, promoting caspase-3 and Bax expressions (3 C-3 F). This suggests that Bupivacaine is available to signally promote CRC cell apoptosis.

3.4 Bupivacaine promoted CRC cell autophagy

Examined the influence of receiving 1 mM Bupivacaine in 24 or 48 h on autophagy-related protein expression in CRC through Western blot. After treatment, Beclin-1 expression and LC3B II/LC3B I ratio were elevated signally while p62 expression was decreased in SW480 and SW620 cells (Figure 4a-4d). It suggested that Bupivacaine is available to signally promote CRC cell autophagy.

3.5 Bupivacaine inhibited NF-κB activation in CRC cells

Our work examined the influence of receiving 1 mM Bupivacaine on NF-κB activation in CRC cells through immunofluorescence (IF). As shown in Figure 5a-5d, after treating SW480 and SW620 cells with Bupivacaine in 24 or 48 h, active NF-κB fluorescence intensity was signally reduced with time dependence. This suggests that Bupivacaine is available to signally inhibit CRC cell activation.

3.6 Bupivacaine inhibited CRC inflammation factors

Examined the influence of receiving 1 mM Bupivacaine in 24 or 48 h on inflammation factors

Figure 4. Bupivacaine Promoted CRC Cell Autophagy.
Note: A: Western Blot For Checking LC3B, Beclin-1 And P62 Protein Expression Levels In SW480 And SW620 Cells After Receiving 1 mm Bupivacaine In 24 h; B: Western Blot For Checking LC3B, Beclin-1 And P62 Protein Expression Levels In SW480 And SW620 Cells After Receiving 1 mm Bupivacaine In 48 h; Data Shown In Mean ± SD (N = 3); One-Way ANOVA For Calculating The Significance Of Each Group; Applying The Tukey Test For Correcting The Variance. *P< 0.05.
of carcinoma of colon and rectum through ELISA. As shown in Figure 6a and 6b, after treating SW480 and SW620 cells with 1 mM Bupivacaine in 24 or 48 h, IL-1 beta, IL-6, and TNF-α levels were visually reduced. This suggests that Bupivacaine is available to signally inhibit CRC inflammation.

3. 7 Bupivacaine inhibited CRC NF-κB signaling pathway

Next, our work examined the influence of receiving 1 mM Bupivacaine in 24 or 48 h on CRC NF-κB signaling pathway through western blot. As shown in Figure 7a and 7b, Bupivacaine significantly reduced NF-κB, phosphorylation IKK and IκB levels in SW480 and SW620 cells. This suggests that Bupivacaine is available to signally inhibit CRC NF-κB signaling pathway.

3. 8 Bupivacaine inhibited tumor growth in the body

To further prove our findings, our work conducted in vivo experiments. In order to determine the optimal dose, 5 different doses of bupivacaine (2.15, 4.30, 6.45, 8.60, 10.75 mM) were injected into the nude mice implanted with tumors, and it was found that 4.3 mM began to have inhibitory effect on tumor and 8.6 mM began to obtain the maximum inhibitory effect (results not shown), so 4.3 mM and 8.6 mM bupivacaine were chosen for administration. Based on the findings, 4.3 mM and 8.6 mM Bupivacaine obviously inhibited mice volume and weight (Figure 8a). Additionally, western blot findings revealed that Bupivacaine obviously inhibited NF-κB phosphorylation in CRC in the body (Figure 8b). This suggests that Bupivacaine inhibits rectal cancer growth in the body.

4 Discussions

In this research, we found that Bupivacaine signally inhibits CRC cell activity while promoting its apoptosis and autophagy. Further studies have shown that Bupivacaine links with Bcl-2, Bax and caspase-3 gene expressions regulating apoptosis, and with the autophagy-related p62, Beclin-1, and LC3B expression proteins. Additionally, our team have found that Bupivacaine signally inhibits phosphorylation of proteins IKK, IκB and NF-κB relative to NF-κB signaling pathway in cells.

Inducing cancer cell apoptosis is among the vital indicators to evaluate the anti-tumor drugs inhibiting cancer cells growth [16,17]. Studies by Bundscherer A et al. have shown that Bupivacaine inhibits colon cancer cell proliferation, but has no significant impact on colon cancer cell apoptosis. We found that 1 mM Bupivacaine signally inhibits
CRC cell apoptosis rate, possibly because the drugs we used was at much higher concentration than that by Bundscherer A et al. Bax is a pro-apoptosis protein, which elevates mitochondrial membrane permeability after receiving apoptosis signal, resulting in decreased membrane potential and promoting the release of apoptosis factors to cyto- kines. While Bcl-2 in case of mitochondrial membrane damage is available to repair mitochondrial control and reduce mitochondrial membrane permeability, thus playing an anti-apoptosis effect [18,19]. Additionally, cysteine aspartic acid specific protease can inhibit apoptosis [20] when activated.

In this work, we found that 1 mM Bupivacaine visually elevated mRNA expression in Bax and caspase-3 while inhibited it in Bcl-2. In addition, ropivacaine can also inhibit the migration of colorectal cancer, which is consistent with previous studies [21].

Cancer cell autophagy is a process of degrading damaged cell organs or proteins in the eukaryotic cells. Amidst preventing and treating cancer, the search for reliable cancer cell autophagy regulators has become a heated topic for scientists [22,23]. Beclin-1, p62, and LC3B are key proteins involved in cell autophagy regulation. Beclin-1 is responsible for collecting autophagy protein and initiating autophagy [24]. As for p62 protein, a suitable
protein between autophagy and substrate, acts as a molecular regulator during autophagy. LC3 forms LC3B I through participating in ubiquitination, which is later lipidized into LC3B II. LC3B II/LC3B I ratio can be regarded as a marker of autophagy degradation [25]. Previously published research has shown that anesthetics act actively in regulating cell autophagy [26]. In this research, we found that Bupivacaine observably elevated LC3B II/LC3B I ration and Beclin-1 expression while inhibited p62 expression.

A great many studies have revealed that activating NF-B signaling pathway acts pivotally in the process of CRC cell proliferation, apoptosis, angiogenesis as well as metastasis [27,28]. During activating NF-κB, TLR4 receptor binding to ligand results in activating IKK complex, while IKK activation further promotes IкB phosphorylation, which then triggers the release of NF-κB from nucleus and further stimulates the release of inflammatory factors [29]. In CRC occurrence, the role of inflammation in tumor microenvironment is unquestionable. Immunotherapy for
NF-κB has great potential in improving the survival rate of CRC patients. Studies have implied that Bupivacaine acts actively in treating diseases through inhibiting the NF-κB signaling pathway activation. We found that Bupivacaine visually inhibited IKK phosphorylation, IkB phosphorylation and NF-κB expression in CRC cells, a process that may have beneficial impact on inhibiting CRC proliferation while promoting apoptosis and autophagy.

5 Conclusion

To sum up, our findings prove that Bupivacaine inhibits CRC proliferation through blocking the NF-κB signaling pathway activation, promoting apoptosis and autophagy, thus providing strong data support for Bupivacaine as a drug for CRC in the future.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| Nuclear factor κB | NF-κB |
| colorectal cancer | CRC |
| 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide | MTT |
| Interleukin 1β | IL-1β |
| Tumor Necrosis Factor α | TNF-α |
| Interleukin 6 | IL-6 |
| Real-time fluorescence quantitative PCR | qRT-PCR |
| Glyceraldehyde-3-phosphate dehydrogenase | GAPDH |
| inhibitor of NF-κB | IκB |
| Phosphorylated IκB | p-IκB |
| IκB kinase | IKK |
| Phosphorylated IKK | p-IKK |
| Microtubule-associated protein light chain 3B | LC3B |

Disclosure of potential conflicts of interest

No potential conflict of interest was reported by the author(s).

References

[1] Zhang J, Deng X. Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes. Exp Ther Med. 2017;13(3):1074–1080.
[2] Yu L, Li L, Medeiros LJ, et al. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev. 2017;31(2):77–92.
[3] Ye F, Zuo ZY. Anesthetic effects on autophagy. Med Gas Res. 2017;7(3):204–211.
[4] Xuan W, Zhao H, Hankin J, et al. Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro. Sci Rep. 2016;6(1):26277.
[5] Xia F, Liu P, Li M. The regulatory factors and pathological roles of autophagy-related protein 4 in diverse diseases: recent research advances. Med Res Rev. 2021;41(3):1644–1675.
[6] Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87. PMID: 21943236
[7] Vega-Rubin-de-Celis S, Kinch L, Peña-Llopis S. Regulation of Beclin 1-Mediated Autophagy by Oncogenic Tyrosine Kinases. Int J Mol Sci. 2020;21(23):9210.
[8] Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.
[9] Provenzale D, Gupta S, Ahnen DJ, et al. NCCN Guidelines Insights: colorectal Cancer Screening, Version 1.2018. J Natl Compr Canc Netw. 2018;16 (8):939–949.
[10] Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–4147.
[11] Patel M, Horgan PG, McMillan DC, et al. NF-κB pathways in the development and progression of colorectal cancer. Transl Res. 2018;197:43–56.
[12] Onorati AV, Dyczynski M, Ojha R, et al. Targeting autophagy in cancer. Cancer. 2018;124(16):3307–3318.
[13] Cheng L, Cao H, Xu J, et al. Circ_RPL23A acts as a miR-1233 sponge to suppress the progression of clear cell renal cell carcinoma by promoting ACAT2. J Bioenerg Biomembr. 2021. doi:10.1007/s10863-021-09901-8
[14] Wang T, Mao P, Feng Y, et al. Blocking hsa_circ_0006168 suppresses cell proliferation and motility of human glioblastoma cells by regulating hsa_circ_0006168/miR-628-5p/IGF1R ceRNA axis. Cell Cycle (Georgetown, Tex). 2021; 1–14.
[15] Li Y, Tang Y, Li Z, et al. CircSOS2 promotes cervical squamous cell carcinoma by regulation of proliferation, cell cycle, apoptosis, migration, invasion, and glycolysis by targeting miR-543/FNDC3B axis. Archives of biochemistry and biophysics. 2021:108925.
[16] Marshall RS, Vierstra RD. Dynamic Regulation of the 26S Proteasome: from Synthesis to Degradation. Front Mol Biosci. 2019;6:40.
[17] Li T, Chen L, Zhao H, et al. Both Bupivacaine and Levobupivacaine inhibit colon cancer cell growth but not melanoma cells in vitro. J Anesth. 2019;33(1):17–25.
[18] Li R, Xiao C, Liu H, et al. Effects of local anesthetics on breast cancer cell viability and migration. BMC Cancer. 2018;18(1):666.
[19] Kim B, Lee H, Chung H, et al. The efficacy of topical bupivacaine and triamcinolone acetonide injection in the relief of pain after endoscopic submucosal dissection for gastric neoplasia: a randomized double-blind, placebo-controlled trial. Surg Endosc. 2015;29 (3):714–722.

[20] Kanemitsu Y, Shitara K, Mizusawa J, et al. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): a Randomized Clinical Trial. J Clin Oncol. 2021;39(10):1098–1107.

[21] Wang X, Li T. Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1. Bioengineered. 2021;12(1):44–53.

[22] Hauseman ZJ, Harvey EP, Newman CE, et al. Homogeneous Oligomers of Pro-apoptotic BAX Reveal Structural Determinants of Mitochondrial Membrane Permeabilization. Mol Cell. 2020;79(1):68–83.e7.

[23] Guo D, Li K, Yang M, et al. Levobupivacaine attenuates lipopolysaccharide-induced acute lung injury. Fundam Clin Pharmacol. 2016;30(4):307–315.

[24] Fares KM, Mohamed SA, Abd El-Rahman AM, et al. Efficacy and safety of intraperitoneal dexmedetomidine with bupivacaine in laparoscopic colorectal cancer surgery, a randomized trial. Pain Med. 2015;16 (6):1186–1194.

[25] Fan L, Wu Y, Wang J, et al. Sevoflurane inhibits the migration and invasion of colorectal cancer cells through regulating ERK/MMP-9 pathway by up-regulating miR-203. Eur J Pharmacol. 2019;850:43–52.

[26] Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–664.

[27] Eden C, Esses G, Katz D, et al. Effects of anesthetic interventions on breast cancer behavior, cancer-related patient outcomes, and postoperative recovery. Surg Oncol. 2018;27(2):266–274.

[28] de Ridder I, Kerkhofs M, Veettil SP, et al. Cancer cell death strategies by targeting Bcl-2’s BH4 domain. Biochim Biophys Acta Mol Cell Res. 2021;1868 (5):118983.

[29] Dan J, Gong X, Li D, et al. Inhibition of gastric cancer by local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade. Biomed Pharmacother. 2018;103:823–828.